RESULT UPDATE



KEY DATA

Rating	BUY
Sector relative	Outperformer
Price (INR)	677
12 month price target (INR)	781
52 Week High/Low	699/459
Market cap (INR bn/USD bn)	550/6.4
Free float (%)	72.1
Avg. daily value traded (INR mn)	1,488.1

SHAREHOLDING PATTERN

	Mar-25	Dec-24	Sep-24
Promoter	32.52%	32.52%	32.35%
FII	34.22%	34.51%	33.64%
DII	17.64%	15.74%	15.32%
Pledge	0.91%	0%	0%

Achieves growth and prudence

UPL in Q4FY25 and FY25 reported an industry-leading performance with a strong volume recovery. Improvement in working capital (by 33) days), astute debt reduction (~USD1bn) and EBITDA growth guidance of 10–14%, going into FY26, mark strong scalars and vectors for UPL.

We are moderating FY26 estimates marginally to factor in a gradual pickup in volumes and reckon FY27 shall log accelerated growth led by the NPP portfolio (USD1.5bn target by FY30), specialty chemicals business and global crop protection business. Maintain 'BUY'. We are reducing FY26E EPS by 14.0% and raising FY27E EPS by 5%, yielding a revised TP of INR781, valuing UPL at 13x Q4FY27E EPS.

FINANCIALS (INR mn)

Year to March	FY24A	FY25E	FY26E	FY27E
Revenue	430,990	466,370	501,084	542,559
EBITDA	55,160	81,200	92,410	113,719
Adjusted profit	290	18,250	31,018	47,781
Diluted EPS (INR)	0.4	23.0	39.0	60.1
EPS growth (%)	(99.4)	5,836.9	70.0	54.0
RoAE (%)	(4.2)	3.0	9.3	13.0
P/E (x)	1,750.9	29.5	17.4	11.3
EV/EBITDA (x)	13.8	8.4	8.0	6.1
Dividend yield (%)	0.1	0.9	1.4	2.2

Strong product pipeline and healthy innovation turnover

UPL's innovation strategy is driving its robust performance, with USD100mn revenue from new crop protection products and a 14% innovation rate. Approximately 38% of the portfolio is now differentiated and sustainable, with 45–50% targeted by FY27. In FY25, the NPP business logged more than 20% growth, and differentiated products such as Feroce and Evolution fuelled 21% volume growth, particularly in Brazil and North America. Superform (specialty chemicals) also delivered 24% revenue growth, backed by backward integration, platform investments, and new high-potential contract wins. The company expects to launch 20 more products in FY26 and is aiming for USD1.5bn in risk-adjusted annual sales by FY30.

CHANGE IN ESTIMATES

	Revised 6	Revised estimates		sion
Year to March	FY26E	FY27E	FY26E	FY27E
Revenue	501,084	542,559	-2.5	-4.0
EBITDA	92,410	113,719	-8.4	2.5
Adjusted profit	31,018	47,781	-8.9	11.3
Diluted EPS (INR)	39.0	60.1	-14	5.0

EBITDA growth guidance of 10–14%

UPL expects growth to largely come from North America, Latam and RoW. It is mostly expecting volume-led growth of 4-8% in FY26. The differentiated offerings, new products from specialty chemicals and drive to achieve better sales from corn seeds can be potential margin drivers. Management expects the better part of its guidance to take shape in H2FY26 and H1FY26 could be rather muted.

Deleveraging and asset monetisation enhance balance sheet

UPL made significant progress in reducing net debt, bringing it down to INR138.6bn, with net debt/EBITDA falling to 1.7x from 4x a year ago. Key contributors included a INR33.7bn working capital release (driven by inventory and receivables efficiency), a USD200mn rights issue and partial monetisation of Advanta stake for USD350mn. The company also prepaid USD250mn of long-term loans. Given strong internal cash generation, improved working capital cycles and asset-light growth in seeds and specialty chemicals, UPL's balance sheet is well positioned.

PRICE PERFORMANCE



Financials

Year to March	Q4FY25	Q4FY24	% Change	Q3FY25	% Change
Net Revenue	155,730	140,780	10.6	109,070	42.8
EBITDA	32,370	19,320	67.5	21,620	49.7
Adjusted Profit	10,304	394	2,515.4	7,667	34.4
Diluted EPS (INR)	13.3	0.5	2,431.0	9.9	34.4

Archit Joshi Archit.Joshi@nuvama.com Rohan Ohri rohan.ohri@nuvama.com

Financial Statements

Income Statement (INR mn)

Year to March	FY24A	FY25E	FY26E	FY27E
Total operating income	430,990	466,370	501,084	542,559
Gross profit	186,050	224,140	250,542	282,131
Employee costs	46,820	53,090	58,399	62,195
Other expenses	84,070	89,850	99,734	106,216
EBITDA	55,160	81,200	92,410	113,719
Depreciation	27,630	27,500	28,158	29,186
Less: Interest expense	38,520	36,270	23,669	19,720
Add: Other income	4,830	4,860	5,103	5,562
Profit before tax	(20,860)	8,290	45,686	70,376
Prov for tax	(2,090)	90	7,767	11,964
Less: Other adj	0	0	0	0
Reported profit	(11,990)	8,970	31,018	47,781
Less: Excp.item (net)	12,280	9,280	0	0
Adjusted profit	290	18,250	31,018	47,781
Diluted shares o/s	750	795	795	795
Adjusted diluted EPS	0.4	23.0	39.0	60.1
DPS (INR)	1.0	6.0	9.5	14.7
Tax rate (%)	10.0	1.1	17.0	17.0

Balance Sheet (INR mn)

zalance sheet (mit inn)					
Year to March	FY24A	FY25E	FY26E	FY27E	
Share capital	1,500	1,590	1,590	1,590	
Reserves	276,430	320,400	346,648	386,845	
Shareholders funds	277,930	321,990	348,238	388,435	
Minority interest	49,130	56,270	64,612	77,463	
Borrowings	284,380	237,140	212,140	192,140	
Trade payables	156,840	108,670	116,531	126,176	
Other liabs & prov	31,070	25,940	25,755	25,963	
Total liabilities	875,460	880,020	829,454	878,435	
Net block	84,430	81,070	74,062	66,026	
Intangible assets	312,070	315,840	315,840	315,840	
Capital WIP	11,060	6,150	6,150	6,150	
Total fixed assets	407,560	403,060	396,052	388,016	
Non current inv	18,930	20,080	20,080	20,080	
Cash/cash equivalent	60,360	95,370	12,877	40,283	
Sundry debtors	163,540	155,050	167,028	180,853	
Loans & advances	430	460	1,228	787	
Other assets	205,130	179,160	209,039	221,928	
Total assets	875,460	880,020	829,454	878,435	

Important Ratios (%)

Year to March	FY24A	FY25E	FY26E	FY27E
India growth (%)	(0.2)	0.1	0.1	0.1
America growth (%)	(0.6)	0.5	0.1	0.1
Europe growth (%)	(0.1)	0.3	0.1	0.1
EBITDA margin (%)	12.8	17.4	18.4	21.0
Net profit margin (%)	0.1	3.9	6.2	8.8
Revenue growth (% YoY)	(19.6)	8.2	7.4	8.3
EBITDA growth (% YoY)	(50.6)	47.2	13.8	23.1
Adj. profit growth (%)	(99.4)	6,193.1	70.0	54.0

Free Cash Flow (INR mn)

Year to March	FY24A	FY25E	FY26E	FY27E
Reported profit	(16,360)	12,920	37,919	58,412
Add: Depreciation	27,630	27,500	28,158	29,186
Interest (net of tax)	38,520	36,270	23,669	19,720
Others	(2,760)	(13,710)	3,674	(3,357)
Less: Changes in WC	(20,550)	41,410	(102,766)	(10,321)
Operating cash flow	26,480	104,390	(9,345)	93,640
Less: Capex	(28,940)	(23,000)	(21,150)	(21,150)
Free cash flow	(2,460)	81,390	(30,495)	72,490

Assumptions (%)

Year to March	FY24A	FY25E	FY26E	FY27E
GDP (YoY %)	5.8	6.3	6.3	6.3
Repo rate (%)	5.5	5.0	5.0	5.0
USD/INR (average)	78.0	77.0	77.0	77.0
LATAMgrowth (%)	(0.2)	0	0.1	0.1
RoW growth (%)	0.1	(0.1)	0.1	0.1
Gross margin (%)	0.4	0.5	0.5	0.5
Net Debt/EBITDA (x)	4.1	1.7	2.2	1.3

Key Ratios

Year to March	FY24A	FY25E	FY26E	FY27E
RoE (%)	(4.2)	3.0	9.3	13.0
RoCE (%)	5.4	9.5	11.2	14.0
Inventory days	199	174	166	183
Receivable days	146	125	117	117
Payable days	248	200	164	170
Working cap (% sales)	48.2	50.1	52.9	52.5
Gross debt/equity (x)	0.9	0.6	0.5	0.4
Net debt/equity (x)	0.7	0.4	0.5	0.3
Interest coverage (x)	0.7	1.5	2.7	4.3

Valuation Metrics

Year to March	FY24A	FY25E	FY26E	FY27E
Diluted P/E (x)	1,750.9	29.5	17.4	11.3
Price/BV (x)	1.8	1.7	1.5	1.4
EV/EBITDA (x)	13.8	8.4	8.0	6.1
Dividend yield (%)	0.1	0.9	1.4	2.2

Source: Company and Nuvama estimates

Valuation Drivers

Year to March	FY24A	FY25E	FY26E	FY27E
EPS growth (%)	(99.4)	5,836.9	70.0	54.0
RoE (%)	(4.2)	3.0	9.3	13.0
EBITDA growth (%)	(50.6)	47.2	13.8	23.1
Payout ratio (%)	nm	53.2	24.4	24.4

UPL

Exhibit 1: Quarterly financial snapshot (INR mn)

Revenues 155,730 140,780 1.06 199,070 42.8 466,313 513,692 565,662 Raw material 85,510 90,090 (5.1) 53,290 60.5 237,820 251,709 276,880 Staff costs 14,510 10,360 40.1 11,840 22.6 51,502 56,652 62,317 Other expenditure 23,340 21,010 11.1 22,220 4.6 94,999 104,499 114,940 Check 0 0 0 0 0 0 0 41.1 384,321 412,860 454,147 Check 0 0 0 0 0 0 0 49.7 81,992 100,832 110,915 Depreciation 7,050 7,940 (11.2) 6,880 2.5 27,408 30,251 33,900 EBIT 25,320 11,380 14,740 54,585 70,581 77,016 Less: Interest Expense 9,140 10,900 (15.1)									
Raw material 85,510 90,090 (5.1) 53,290 60.5 237,820 251,709 276,886 Staff costs 14,510 10,360 40.1 11,840 22.6 51,502 56,652 62,317 Other expenditure 23,340 21,010 11.1 22,320 4.6 94,999 104,499 114,949 Check 0 0 0 0 0 0 0 0 81,932 10,983 110,915 Check 0 0 0 0 0 0 81,992 100,832 110,915 Depreciation 7,050 7,940 (11.2) 6,880 2.5 27,408 30,251 77,016 Less: Interest Expense 9,140 10,900 (16.1) 7,300 25.2 35,309 24,924 18,382 Add: Other income 1,070 1,260 (15.1) 1,700 (37.1) 4,854 5,097 5,352 Profits Edefore Tax 1,7250 1,740	Year to March	4QFY25	4QFY24	% YOY	Q3FY25	% QoQ	FY25E	FY26E	FY27E
Staff costs 14,510 10,360 40.1 11,840 22.6 51,502 56,652 63,317 Other expenditure 23,340 21,010 11.1 22,320 4.6 94,999 104,499 114,945 Total expenditure 123,360 121,460 1.6 87,450 41.1 384,321 412,860 454,147 Check 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Revenues	155,730	140,780	10.6	109,070	42.8	466,313	513,692	565,062
Other expenditure 23,340 21,010 11.1 22,320 4.6 94,999 104,499 114,945 Total expenditure 123,360 121,460 1.6 87,450 41.1 384,321 412,860 454,147 Check 0 0 0 0 0 10 10 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 10,915 11,917 10,915 11,917 11,917 11,917 11,917 11,917 11,917 11,917 11,917 11,917 11,917 11,917 11,917 11,917 11,917 11,917 11,917 11,917 11,917 11,917 11,917 11,917 </td <td>Raw material</td> <td>85,510</td> <td>90,090</td> <td>(5.1)</td> <td>53,290</td> <td>60.5</td> <td>237,820</td> <td>251,709</td> <td>276,880</td>	Raw material	85,510	90,090	(5.1)	53,290	60.5	237,820	251,709	276,880
Total expenditure 123,360 121,460 1.6 87,450 41.1 384,321 412,860 454,147 Check 0 0 0 0 0 0 EBITDA 32,370 19,320 67.5 21,620 49.7 81,992 100,832 110,915 Depreciation 7,050 7,940 (11.2) 6,880 2.5 27,408 30,251 33,900 EBIT 25,320 11,380 14,740 54,585 70,581 77,016 Less: Interest Expense 9,140 10,900 (16.1) 7,300 25.2 35,309 24,924 18,382 Add: Other income 1,070 1,260 (15.1) 1,700 (37.1) 4,854 5,097 5,352 Profit Before Tax 17,250 1,740 891.4 9,140 88.7 24,130 50,754 63,986 Less: Provision for Tax 2,980 1,100 170.9 (4,990) 2,903 9,136 11,517 Less: Minority I	Staff costs	14,510	10,360	40.1	11,840	22.6	51,502	56,652	62,317
Check 0 0 0 0 EBITDA 32,370 19,320 67.5 21,620 49.7 81,992 100,832 110,915 Depreciation 7,050 7,940 (11.2) 6,880 2.5 27,408 30,251 33,900 EBIT 25,320 11,380 14,740 54,585 70,581 77,016 Less: Interest Expense 9,140 10,900 (16.1) 7,300 25.2 35,309 24,924 18,382 Add: Other income 1,070 1,260 (15.1) 1,700 (37.1) 4,854 5,097 5,352 Profit Before Tax 17,250 1,740 891.4 9,140 88.7 24,130 50,754 63,986 Less: Provision for Tax 2,980 1,100 170.9 (4,990) 2,903 9,136 11,517 Less: Minority Interest (1,830) (1,200) 52.5 (250) 632.0 6,000 7,574 9,546 Add: Share of profit from associates <td< td=""><td>Other expenditure</td><td>23,340</td><td>21,010</td><td>11.1</td><td>22,320</td><td>4.6</td><td>94,999</td><td>104,499</td><td>114,949</td></td<>	Other expenditure	23,340	21,010	11.1	22,320	4.6	94,999	104,499	114,949
EBITDA 32,370 19,320 67.5 21,620 49.7 81,992 100,832 110,915 Depreciation 7,050 7,940 (11.2) 6,880 2.5 27,408 30,251 33,900 EBIT 25,320 11,380 14,740 54,585 70,581 77,016 Less: Interest Expense 9,140 10,900 (16.1) 7,300 25.2 35,309 24,924 18,382 Add: Other income 1,070 1,260 (15.1) 1,700 (37.1) 4,854 5,097 5,352 Profit Before Tax 17,250 1,740 891.4 9,140 88.7 24,130 50,754 63,986 Less: Provision for Tax 2,980 1,100 170.9 (4,990) 2,903 9,136 11,517 Less: Provision for Tax 2,980 1,100 170.9 (4,990) 2,903 9,136 11,517 Less: Provision for Tax 1,830 (1,200) 52.5 (250) 632.0 6,000 7,574	Total expenditure	123,360	121,460	1.6	87,450	41.1	384,321	412,860	454,147
Depreciation 7,050 7,940 (11.2) 6,880 2.5 27,408 30,251 33,900 EBIT 25,320 11,380 14,740 54,585 70,581 77,016 Less: Interest Expense 9,140 10,900 (16.1) 7,300 25.2 35,309 24,924 18,382 Add: Other income 1,070 1,260 (15.1) 1,700 (37.1) 4,854 5,097 5,352 Profit Before Tax 17,250 1,740 891.4 9,140 88.7 24,130 50,754 63,986 Less: Provision for Tax 2,980 1,100 170.9 (4,990) 2,903 9,136 11,517 Less: Minority Interest (1,830) (1,200) 52.5 (250) 632.0 6,000 7,574 9,549 Add: Share of profit from associates (270) 450 (2,780) 0 0 0 0 0 Reported Profit 8,960 400 2,140.0 8,280 8.2 15,26 <t< td=""><td>Check</td><td>0</td><td>0</td><td></td><td>0</td><td></td><td></td><td></td><td></td></t<>	Check	0	0		0				
EBIT 25,320 11,380 14,740 54,585 70,581 77,016 Less: Interest Expense 9,140 10,900 (16.1) 7,300 25.2 35,309 24,924 18,382 Add: Other income 1,070 1,260 (15.1) 1,700 (37.1) 4,854 5,097 5,352 Profit Before Tax 17,250 1,740 891.4 9,140 88.7 24,130 50,754 63,986 Less: Provision for Tax 2,980 1,100 170.9 (4,990) 2,903 9,136 11,517 Less: Minority Interest (1,830) (1,200) 52.5 (250) 632.0 6,000 7,574 9,545 Add: Share of profit from associates (270) 450 (2,780) 0 0 0 Add: Exceptional items (net of tax) (2,316) (6) (1,113) 0 0 0 Reported Profit 8,960 400 2,140.0 8,280 8.2 15,226 34,043 42,915 Adjusted Profit 6,644 394 1,586.3 7,167 (7.3) 11,726 34,043 42,915 Equity capital (FV INR 2) 1,550 1,500 1,550 1,550 1,500 1,500 No. of Diluted shares outstanding (mn) 775 750 775 750 750 750 Adjusted Diluted EPS 8.6 0.5 1,531.9 9.2 (7.3) 15.6 45.4 57.2 As % of net revenues Raw material 54.9 64.0 (908.4) 48.9 605.1 51.0 49.0 49.0 Staff expenses 9.3 7.4 10.9 11.0 11.0 11.0 Other expenses 15.0 14.9 20.5 20.4 20.3 20.3 EBITDA 20.8 13.7 706.2 19.8 96.4 17.6 19.6 19.6	EBITDA	32,370	19,320	67.5	21,620	49.7	81,992	100,832	110,915
Less: Interest Expense 9,140 10,900 (16.1) 7,300 25.2 35,309 24,924 18,382 Add: Other income 1,070 1,260 (15.1) 1,700 (37.1) 4,854 5,097 5,352 Profit Before Tax 17,250 1,740 891.4 9,140 88.7 24,130 50,754 63,986 Less: Provision for Tax 2,980 1,100 170.9 (4,990) 2,903 9,136 11,517 Less: Minority Interest (1,830) (1,200) 52.5 (250) 632.0 6,000 7,574 9,545 Add: Share of profit from associates (270) 450 (2,780) 0 0 0 0 C Add: Exceptional items (net of tax) (2,316) (6) (1,113) 0 0 0 0 C Add: Exceptional items (net of tax) (2,316) (6) (1,113) 0 0 0 0 C Add: Exceptional items (net of tax) (2,316) (6) (1,113) 0 0 0 0 C Add: Exceptional items (net of tax) (2,316) (6) (1,113) 0 0 0 0 C Add: Exceptional items (net of tax) (2,316) (6) (1,113) 0 0 0 0 C Add: Exceptional items (net of tax) (2,316) (6) (1,113) 0 0 0 0 0 C Add: Exceptional items (net of tax) (2,316) (6) (1,113) 0 0 0 0 0 C Add: Exceptional items (net of tax) (2,316) (6) (1,113) 0 0 0 0 0 0 C Add: Exceptional items (net of tax) (2,316) (6) (1,113) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Depreciation	7,050	7,940	(11.2)	6,880	2.5	27,408	30,251	33,900
Add: Other income 1,070 1,260 (15.1) 1,700 (37.1) 4,854 5,097 5,352 Profit Before Tax 17,250 1,740 891.4 9,140 88.7 24,130 50,754 63,986 Less: Provision for Tax 2,980 1,100 170.9 (4,990) 2,903 9,136 11,517 Less: Minority Interest (1,830) (1,200) 52.5 (250) 632.0 6,000 7,574 9,549 Add: Share of profit from associates (270) 450 (2,780) 0 0 0 0 Add: Exceptional items (net of tax) (2,316) (6) (1,113) 0 0 0 0 Reported Profit 8,960 400 2,140.0 8,280 8.2 15,226 34,043 42,915 Adjusted Profit 6,644 394 1,586.3 7,167 (7.3) 11,726 34,043 42,915 Equity capital (FV INR 2) 1,550 1,500 1,500 1,550 1,500 1,500 1,500 Adjusted Diluted shares outstanding (mn) 775 750 775 750 750 750 Adjusted Diluted EPS 8.6 0.5 1,531.9 9.2 (7.3) 15.6 45.4 57.2 As % of net revenues Raw material 54.9 64.0 (908.4) 48.9 605.1 51.0 49.0 49.0 Staff expenses 9.3 7.4 10.9 11.0 11.0 11.0 11.0 Other expenses 15.0 14.9 20.5 20.4 20.3 20.3 EBITDA 20.8 13.7 706.2 19.8 96.4 17.6 19.6 19.6 19.6 EBITDA	EBIT	25,320	11,380		14,740		54,585	70,581	77,016
Profit Before Tax 17,250 1,740 891.4 9,140 88.7 24,130 50,754 63,986 Less: Provision for Tax 2,980 1,100 170.9 (4,990) 2,903 9,136 11,517 Less: Minority Interest (1,830) (1,200) 52.5 (250) 632.0 6,000 7,574 9,549 Add: Share of profit from associates (270) 450 (2,780) 0 0 0 0 0 Add: Exceptional items (net of tax) (2,316) (6) (1,113) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Less: Interest Expense	9,140	10,900	(16.1)	7,300	25.2	35,309	24,924	18,382
Less: Provision for Tax 2,980 1,100 170.9 (4,990) 2,903 9,136 11,517 Less: Minority Interest (1,830) (1,200) 52.5 (250) 632.0 6,000 7,574 9,549 Add: Share of profit from associates (270) 450 (2,780) 0 0 0 0 Add: Exceptional items (net of tax) (2,316) (6) (1,113) 0 0 0 0 Reported Profit 8,960 400 2,140.0 8,280 8.2 15,226 34,043 42,919 Equity capital (FV INR 2) 1,550 1,500 1,550 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500	Add: Other income	1,070	1,260	(15.1)	1,700	(37.1)	4,854	5,097	5,352
Less: Minority Interest (1,830) (1,200) 52.5 (250) 632.0 6,000 7,574 9,545 Add: Share of profit from associates (270) 450 (2,780) 0 0 0 0 Add: Exceptional items (net of tax) (2,316) (6) (1,113) 0 0 0 0 Reported Profit 8,960 400 2,140.0 8,280 8.2 15,226 34,043 42,919 Adjusted Profit 6,644 394 1,586.3 7,167 (7.3) 11,726 34,043 42,919 Equity capital (FV INR 2) 1,550 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500	Profit Before Tax	17,250	1,740	891.4	9,140	88.7	24,130	50,754	63,986
Add: Share of profit from associates (270) 450 (2,780) 0 0 0 Condition of tax) (2,316) (6) (1,113) 0 0 0 0 Condition of tax (2,316) (6) (1,113) 0 0 0 0 Condition of tax (2,316) (6) (1,113) 0 0 0 0 Condition of tax (2,316) (6) (1,113) 0 0 0 0 Condition of tax (2,316) (3,404) 42,919 (3,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 42,919 (4,404) 4	Less: Provision for Tax	2,980	1,100	170.9	(4,990)		2,903	9,136	11,517
Add: Exceptional items (net of tax) (2,316) (6) (1,113) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Less: Minority Interest	(1,830)	(1,200)	52.5	(250)	632.0	6,000	7,574	9,549
Reported Profit 8,960 400 2,140.0 8,280 8.2 15,226 34,043 42,919 Adjusted Profit 6,644 394 1,586.3 7,167 (7.3) 11,726 34,043 42,919 Equity capital (FV INR 2) 1,550 1,500 1,550 1,500 1,500 1,500 No. of Diluted shares outstanding (mn) 775 750 775 750 750 750 Adjusted Diluted EPS 8.6 0.5 1,531.9 9.2 (7.3) 15.6 45.4 57.2 As % of net revenues Raw material 54.9 64.0 (908.4) 48.9 605.1 51.0 49.0 49.0 Staff expenses 9.3 7.4 10.9 11.0 11.0 11.0 Other expenses 15.0 14.9 20.5 20.4 20.3 20.3 EBITDA 20.8 13.7 706.2 19.8 96.4 17.6 19.6 19.6	Add: Share of profit from associates	(270)	450		(2,780)		0	0	0
Adjusted Profit 6,644 394 1,586.3 7,167 (7.3) 11,726 34,043 42,919 Equity capital (FV INR 2) 1,550 1,500 1,500 1,500 1,500 1,500 No. of Diluted shares outstanding (mn) 775 750 750 750 750 Adjusted Diluted EPS 8.6 0.5 1,531.9 9.2 (7.3) 15.6 45.4 57.2 As % of net revenues Raw material 54.9 64.0 (908.4) 48.9 605.1 51.0 49.0 49.0 Staff expenses 9.3 7.4 10.9 11.0 11.0 11.0 11.0 Other expenses 15.0 14.9 20.5 20.4 20.3 20.3 EBITDA 20.8 13.7 706.2 19.8 96.4 17.6 19.6 19.6	Add: Exceptional items (net of tax)	(2,316)	(6)		(1,113)		0	0	0
Equity capital (FV INR 2) 1,550 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,50	Reported Profit	8,960	400	2,140.0	8,280	8.2	15,226	34,043	42,919
No. of Diluted shares outstanding (mn) 775 750 775 750 750 750 750 75	Adjusted Profit	6,644	394	1,586.3	7,167	(7.3)	11,726	34,043	42,919
Adjusted Diluted EPS 8.6 0.5 1,531.9 9.2 (7.3) 15.6 45.4 57.2 As % of net revenues Raw material 54.9 64.0 (908.4) 48.9 605.1 51.0 49.0 49.0 Staff expenses 9.3 7.4 10.9 11.0 11.0 11.0 Other expenses 15.0 14.9 20.5 20.4 20.3 20.3 EBITDA 20.8 13.7 706.2 19.8 96.4 17.6 19.6 19.6	Equity capital (FV INR 2)	1,550	1,500		1,550		1,500	1,500	1,500
As % of net revenues Raw material 54.9 64.0 (908.4) 48.9 605.1 51.0 49.0 49.0 Staff expenses 9.3 7.4 10.9 11.0 11.0 11.0 11.0 Other expenses 15.0 14.9 20.5 20.4 20.3 20.3 EBITDA 20.8 13.7 706.2 19.8 96.4 17.6 19.6 19.6	No. of Diluted shares outstanding (mn)	775	750		775		750	750	750
Raw material 54.9 64.0 (908.4) 48.9 605.1 51.0 49.0 49.0 Staff expenses 9.3 7.4 10.9 11.0 11.0 11.0 Other expenses 15.0 14.9 20.5 20.4 20.3 20.3 EBITDA 20.8 13.7 706.2 19.8 96.4 17.6 19.6 19.6	Adjusted Diluted EPS	8.6	0.5	1,531.9	9.2	(7.3)	15.6	45.4	57.2
Raw material 54.9 64.0 (908.4) 48.9 605.1 51.0 49.0 49.0 Staff expenses 9.3 7.4 10.9 11.0 11.0 11.0 Other expenses 15.0 14.9 20.5 20.4 20.3 20.3 EBITDA 20.8 13.7 706.2 19.8 96.4 17.6 19.6 19.6									
Staff expenses 9.3 7.4 10.9 11.0 11.0 11.0 Other expenses 15.0 14.9 20.5 20.4 20.3 20.3 EBITDA 20.8 13.7 706.2 19.8 96.4 17.6 19.6 19.6	As % of net revenues								
Other expenses 15.0 14.9 20.5 20.4 20.3 20.3 EBITDA 20.8 13.7 706.2 19.8 96.4 17.6 19.6 19.6	Raw material	54.9	64.0	(908.4)	48.9	605.1	51.0	49.0	49.0
EBITDA 20.8 13.7 706.2 19.8 96.4 17.6 19.6 19.6	Staff expenses	9.3	7.4		10.9		11.0	11.0	11.0
	Other expenses	15.0	14.9		20.5		20.4	20.3	20.3
Net profit 4.3 0.3 398.6 6.6 2.5 6.6 7.6	EBITDA	20.8	13.7	706.2	19.8	96.4	17.6	19.6	19.6
	Net profit	4.3	0.3	398.6	6.6		2.5	6.6	7.6

Source: Company, Nuvama Research

Exhibit 2: Segment details

UPL Corporation															
INR mn	1QFY23	2QFY23	3QFY23	4QFY23	FY23	1QFY24	2QFY24	3QFY24	4QFY24	FY24	1QFY25	2QFY25	3QFY25	4QFY25	FY2
Revenue	76,580	92,880	113,100	137,000	419,560	58,550	74,150	74,130	101,900	308,730	61,400	76,760	84,970	120,700	343,830
YoY(%)	NA	NA	NA	NA	NA	-23.5%	-20.2%	-34.5%	-25.6%	-26.4%	4.9%	3.5%	14.6%	18.4%	11.49
Contribution Profit	30,440	34,490	40,460	40,278	145,668	21,050	24,020	12,390	23,131	80,591	18,390	23,760	30,370	39,228	111,748
Contribution Margin	39.7	37.1	35.8	29%	29%	36.0	32.4	16.7	23%	29%	30.0	31.0	35.7	32.5	32.5
SG&A Expenses	14,310	16,040	17,050	16,400	63,800	15,410	15,840	14,540	13,900	59,690	15,260	16,310	13,830	16,100	61,500
EBITDA	16,130	18,450	23,410	23,878	81,868	5,640	8,180	(2,150)	9,231	20,901	3,130	7,450	16,540	23,128	50,248
EBITDA margins	21.1	19.9	20.7	17.4	19.5	9.6	11.0	-2.9	9.1	6.8	5.1	9.7	19.5	19.2	14.6
Revenue Variance															
Volume	NA	NA	NA	NA		-17.0	1.0	-5.0	-6.0	-7.0	25.0	13.0	14.0	16.0	16.0
Price	NA	NA	NA	NA		-10.0	-25.0	-24.0	-22.0	-22.0	20.0	-8.0	5.0	4.0	-3.0
Exchange	NA	NA	NA	NA		3.0	4.0	1.0	2.0	2.0	0.0	-1.0	-4.0	-2.0	-2.0
Geographies															
Latin America	31,890	54,620	55,830	62,100	204,440	27,080	43,820	38,900	45,800	155,600	24,520	44,470	43,800	45,800	158,590
YoY(%)	NA	NA	NA	NA	NA	-15.1%	-19.8%	-30.3%	-26.2%	-23.9%	-9.5%	1.5%	12.6%	0.0%	1.9%
North America	15,510	10,260	25,250	27,600	78,620	6,600	3,570	8,300	12,900	31,370	10,980	4,150	13,790	24,400	53,320
YoY(%)	NA	NA	NA	NA	NA	-57.4%	-65.2%	-67.1%	-53.3%	-60.1%	66.4%	16.2%	66.1%	89.1%	70.0%
Europe	15,710	12,000	9,990	26,300	64,000	12,280	11,067	5,350	22,900	51,597	13,370	12,580	10,530	29,400	65,880
YoY(%)	NA	NA	NA	NA	NA	-21.8%	-7.8%	-46.4%	-12.9%	-19.4%	8.9%	13.7%	96.8%	28.4%	27.7%
Rest of World	13,470	14,930	21,360	19,900	69,660	11,730	15,600	17,170	18,900	63,400	12,060	15,340	16,470	20,200	64,070
YoY(%)	NA	NA	NA	NA	NA	-12.9%	4.5%	-19.6%	-5.0%	-9.0%	2.8%	-1.7%	-4.1%	6.9%	1.1%
Total	76,580	91,810	112,430	135,900	416,720	57,690	74,057	69,720	100,500	301,967	60,930	76,540	84,590	119,800	341,860
UPL SAS															
Rs mn	1QFY23	2QFY23	3QFY23	4QFY23	FY23	1QFY24	2QFY24	3QFY24	4QFY24	FY24	1QFY25	2QFY25	3QFY25	4QFY25	FY25
Revenue	13,950	13,100	5,580	10,600	43,230	12,030	8,430	3,710	4,290	28,460	10,030	10,130	5,350	6,800	32,310
YoY(%)	NA	NA	NA	NA	NA	-13.8%	-35.6%	-33.5%	-59.5%	-34.2%	-16.6%	20.2%	44.2%	58.5%	13.5%
Contribution Profit	4,410	3680	920	2480	11,490	3,340	1,440	430	250	5,460	2,830	3,040	900	1,890	8,660
Contribution Margin	31.6	28.1	16.5	23.4	26.6	27.8	17.1	11.6	5.8	19.2	28.2	30.0	16.8	27.8	27.8
SG&A Expenses	1,250	1220	1400	1010	4,880	1,200	1,150	1,130	650	4,130	1,140	1,010	1,140	1,000	4,290
EBITDA	3,160	2,460	(480)	1,470	6,610	2,140	290	(700)	(400)	1,330	1,690	2,030	(240)	890	4,370
EBITDA margins	22.7	18.8	-8.6	13.9	15.3	17.9	3.4	-18.9	-9.3	4.7	16.8	20.0	-4.5	13.1	13.5
Advanta															
Rs mn	1QFY23	2QFY23	3QFY23	4QFY23	FY23	1QFY24	2QFY24	3QFY24	4QFY24	FY24	1QFY25	2QFY25	3QFY25	4QFY25	FY25
Revenue	8,420	9,720	9,100	8,350	35,590	10,610	10,700	8,980	11,190	41,480	9,850	11,110	9,990	15,400	46,350
YoY(%)	NA	NA	NA	NA	NA	26.0%	10.1%	-1.3%	34.0%	16.5%	-7.2%	3.8%	11.2%	37.6%	11.7%
Contribution Profit	4,820	5310	5260	4570	19,960	6,620	6,020	5,670	5,380	23,690	5,880	6,380	5,700	8,824	26,784
Contribution Margin	57.2	54.6	57.8	54.7	56.1	62.4	56.3	63.1	48.1	57.1	59.7	57.4	57.1	57.3	57.3
SG&A Expenses	2,450	2580	2650	2690	10,370	2,980	3,370	3,040	2,970	12,360	3,340	3,860	3,460	4,300	14,960
EBITDA	2,370	2,730	2,610	1,880	9,590	3,640	2,650	2,630	2,410	11,330	2,540	2,520	2,240	4,524	11,824
EBITDA margins	28.1	28.1	28.7	22.5	26.9	34.3	24.8	29.3	21.5	27.3	25.8	22.7	22.4	29.4	25.5

Source: Company, Nuvama Research

UPL

Exhibit 3: Yearly net debt/EBITDA (INR mn)

	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Gross debt	286,690	235,600	258,660	229,990	284,380	237,140	212,140	192,140
Perpetual Bonds	29,860	29,860	29,860	29,860	29,860	29,860	29,860	29,860
Total Debt	316,550	265,460	288,520	259,850	314,240	267,000	242,000	222,000
Cash	67,520	48,530	61,200	60,970	60,360	95,370	12,877	40,283
Net Debt including perpetual bonds	249,030	216,930	227,320	198,880	253,880	171,630	229,123	181,717
Net excluding perpetual bond	219,170	187,070	197,460	169,020	224,020	141,770	199,263	151,857
EBITDA	71,040	85,590	101,640	111,600	55,150	81,200	92,410	113,719
Net Debt/EBITDA including perpetual bonds	3.5	2.5	2.2	1.8	4.6	2.1	2.5	1.6
Net Debt/EBITDA excluding perpetual bonds	3.1	2.2	1.9	1.5	4.1	1.7	2.2	1.3

Source: Company, Nuvama Research

Company Description

UPL, incorporated in 1969, is a global player in the agro-chemicals industry with strong presence in off-patent market of US and Europe. UPL ranks among the Top five generic agro-chemical companies in the world. Historically, the company has managed to deliver high growth rates based on its strategy to acquire small agrochemical companies and tail-end brands of big players in US and Europe.

Investment theme

UPL is a direct proxy for increase in demand for food crops due to rising commodity prices, high population growth and high demand for bio-fuel. It has historically focused on acquisitions of smaller companies and brands to achieve higher growth than the market. Moreover large acquisitions like Mancozeb, RiceCo, SIB, DVA Agro, provide further upside. The recent acquisition of Arysta, will further increase UPL's global scale and make it the fifth largest agrochemical player globally.

Key Risks

Demand concerns due to cyclical and seasonal effects

The agro-chemical industry, in general, is cyclical with demands for some products seasonal in nature. Seasonal usage follows varying agricultural seasonal patterns, weather conditions and pest related pressures. This volatility impacts the overall demand for agro-chemicals. This seasonality risk is somewhat mitigated for UPL, given its geographic reach and non-dependence on any one geography for sales.

Volatility in input prices and company's limited ability to pass on costs

The company operates broadly under the concept of 'pass-through', where lower raw material costs benefits are passed on to consumers as lower prices and vice versa. High volatility in prices of raw materials for agro chemicals, leads to lower price realization and can cause margin pressures given that the average holding period of inventory is 3-4 months.

Increase in GM crops usage negative for agro chemicals

Growth in GM crops (biotech products) poses a structural risk to agro-chemicals usage, as GM crops have more resistance to pests and diseases relative to non-GM crops. This could typically lead to reduction in pesticide usage.

Forex Risk

UPL, like most companies with a large export interface, faces risks from an appreciating INR. Further at the operational level company has higher exposure to EUR (given the large exposure from Cerexagri operations) which has been recently been volatile. Most of the forex liabilities are in USD. However, the company has a natural hedge on its imports and on manufacturing done at its international locations.

Additional Data

Management

CEO	Jai Shroff
CFO	Anand Vora
COO	Carlos Pellicer
Chairman	Rajnikant Shroff
Auditor	B S R & Co. LLP

Recent Company Research

Date	Title	Price	Reco
31-Jan-25	Signs of revival; guidance maintained; Result Update	546	Buy
11-Nov-24	UPL (UPLL IN, INR 515, upgrade to BUY) -; Result Update	515	Buy
02-Aug-24	Margin woes persist; Result Update	537	Reduce

Holdings – Top 10*

	% Holding		% Holding
Massachusetts F	4.10	Dimensional Fun	1.03
Vanguard Group	4.03	Lazard	1.02
ICICI Prulife	3.99	Mirae asset	0.77
Blackrock	2.78	HDFC ANC	0.75
Seafarer capita	1.43	FlexShares Trus	0.70

^{*}Latest public data

Recent Sector Research

Date	Name of Co./Sector	Title
02-May-25	Coromandel Int'l	Strong volume growth; Result Update
24-Apr-25	Rallis India	Deficiency of growth triggers; Result Update
09-Apr-25	Agri Inputs	Volume growth likely; margins to stabili: Sector Update

Rating and Daily Volume Interpretation



Source: Bloomberg, Nuvama research

Rating Rationale & Distribution: Nuvama Research

Rating	Expected absolute returns over 12 months	Rating Distribution
Buy	15%	205
Hold	<15% and >-5%	63
Reduce	<-5%	34



DISCLAIMER

Nuvama Wealth Management Limited (defined as "NWML" or "Research Entity") a company duly incorporated under the Companies Act, 1956 (CIN No L67110MH1993PLC344634) having its Registered office situated at 801-804, Wing A, Building No. 3, Inspire BKC, G Block, Bandra Kurla Complex, Bandra East, Mumbai – 400 051 is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, Investment Adviser, Research Analyst and other related activities. Name of Compliance/Grievance officer: Mr. Atul Bapna, E-mail address: comm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mailto:

This Report has been prepared by NWML in the capacity of a Research Analyst having SEBI Registration No.INH000011316 and Enlistment no. 5723 with BSE and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Securities as defined in clause (h) of section 2 of the Securities Contracts (Regulation) Act, 1956 includes Financial Instruments and Currency Derivatives. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in Securities referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NWML and associates, subsidiaries / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report in certain report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. NWML reserves the right to make modifications and alterations to this statement as may be required from time to time. NWML or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NWML is committed to providing independent and transparent recommendation to its clients. Neither NWML nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The

NWML shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the NWML to present the data. In no event shall NWML be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the NWML through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

NWML and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the Securities, mentioned herein or (b) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. (c) NWML may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. (d) The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with NWML (e) Registration granted by SEBI and certification from NISM in no way guarantee performance of NWML or provide any assurance of returns to investors and clients.

NWML or its associates may have received compensation from the subject company in the past 12 months. NWML or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. NWML or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWML or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWML or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or NWML's associates may have financial interest in the subject company. NWML and/or its Group Companies, their Directors, affiliates and/or employees may have interests/positions, financial or otherwise in the Securities/Currencies and other investment products mentioned in this report. NWML, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No

NWML has financial interest in the subject companies: No

NWML's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

NWML has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by NWML on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at www.nseindia.com



Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Additional Disclaimers

Disclaimer for U.S. Persons

This research report is a product of NWML, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by NWML only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, NWML has entered into an agreement with a U.S. registered broker-dealer, Nuvama Financial Services Inc. (formerly Edelweiss Financial Services Inc.) ("NFSI"). Transactions in securities discussed in this research report should be effected through NFSI.

Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA").

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

Disclaimer for Canadian Persons

This research report is a product of NWML, which is the employer of the research analysts who have prepared the research report. The research analysts preparing the research report are resident outside the Canada and are not associated persons of any Canadian registered adviser and/or dealer and, therefore, the analysts are not subject to supervision by a Canadian registered adviser and/or dealer, and are not required to satisfy the regulatory licensing requirements of the Ontario Securities Commission, other Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and are not required to otherwise comply with Canadian rules or regulations regarding, among other things, the research analysts' business or relationship with a subject company or trading of securities by a research analyst.

This report is intended for distribution by NWML only to "Permitted Clients" (as defined in National Instrument 31-103 ("NI 31-103")) who are resident in the Province of Ontario, Canada (an "Ontario Permitted Client"). If the recipient of this report is not an Ontario Permitted Client, as specified above, then the recipient should not act upon this report and should return the report to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any Canadian person.

NWML is relying on an exemption from the adviser and/or dealer registration requirements under NI 31-103 available to certain international advisers and/or dealers. Please be advised that (i) NWML is not registered in the Province of Ontario to trade in securities; (ii) NWML's head office or principal place of business is located in India; (iii) all or substantially all of NWML's assets may be situated outside of Canada; (iv) there may be difficulty enforcing legal rights against NWML because of the above; and (v) the name and address of the NWML's agent for service of process in the Province of Ontario is: Bamac Services Inc., 181 Bay Street, Suite 2100, Toronto, Ontario MSJ 273 Canada.

Disclaimer for Singapore Persons

In Singapore, this report is being distributed by Nuvama Investment Advisors Private Limited (NIAPL) (Previously Edelweiss Investment Advisors Private Limited ("EIAPL")) (Co. Reg. No. 201016306H) which is a holder of a capital markets services license and an exempt financial adviser in Singapore and (ii) solely to persons who qualify as "institutional investors" or "accredited investors" as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Pursuant to regulations 33, 34, 35 and 36 of the Financial Advisers Regulations ("FAR"), sections 25, 27 and 36 of the Financial Advisers Act, Chapter 110 of Singapore shall not apply to NIAPL when providing any financial advisory services to an accredited investor (as defined in regulation 36 of the FAR. Persons in Singapore should contact NIAPL in respect of any matter arising from, or in connection with this publication/communication. This report is not suitable for private investors.

Disclaimer for Hong Kong persons

This report is distributed in Hong Kong by Nuvama Investment Advisors (Hong Kong) Private Limited (NIAHK) (Previously Edelweiss Securities (Hong Kong) Private Limited (ESHK)), a licensed corporation (BOM -874) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to Section 116(1) of the Securities and Futures Ordinance "SFO". This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdictions where their offer or sale is not qualified or exempt from registration. The report also does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of any individual recipients. The Indian Analyst(s) who compile this report is/are not located in Hong Kong and is/are not licensed to carry on regulated activities in Hong Kong and does not / do not hold themselves out as being able to do so.

INVESTMENT IN SECURITIES MARKET ARE SUBJECT TO MARKET RISKS. READ ALL THE RELATED DOCUMENTS CAREFULLY BEFORE INVESTING.

Abneesh Roy Head of Research Committee Abneesh.Roy@nuvama.com